New Comprehensive Blood Safety Portfolio Launched at Arab Health 2014

The RBSS portfolio, the first of its kind in the region, delivers reliability and workflow efficiency for Middle East blood centers, reaffirming RDME’s dedication to providing first class diagnostics in the region.

RBSS now enables patients and communities in the region to benefit from a dedicated, safe and efficient, reliable blood supply. The blood supply is made safe by a reduction in manual steps as well as excellent state-of-the-art assay sensitivity and genotype coverage. With technologies such as electrochemiluminescence (ECL) and polymerase chain reaction (PCR), laboratories benefit from high specificity and NAT real-time-target-discrimination. The systems provide the highest reliability available, excellent traceability and cross-contamination control, and less downtime.

Roche is the first IVD company to have a management center and a logistics hub in the Middle East, enabling RDME to develop from being a regional supplier into becoming a local IVD partner for its customers. The RBSS portfolio safeguards patients through leading technologies with dedication to, and investment in, the safety of the world’s blood supply. “Owing largely to our dedication to safeguard the world’s blood supply through technological innovations and drug development, Roche Diagnostics has become the preferred partner in the Blood Bank Industry,” said Michael Heuer, President of Europe, Middle East, Africa, and Latin America at Roche Diagnostics.

“RBSS benefits from the design, support, and streamlined supply chain that you would associate with [Roche]. We are proud to bring RBSS to the Middle East,” added Moritz Hartmann, General Manager of Roche Diagnostics Middle East. Roche offers service and support for reliability in all its workflow solutions, including the RBSS blood-screening platform, with dependable systems that help blood centers enhance workflow efficiency, minimizing processing time. The RBSS workflow solution is driving the concept of automation and setting new industry standards in diagnostic testing. Molecular testing processes will be brought together in a highly automated solution, without the need for manual transfer steps and with results calculated automatically and sent to the laboratory information system. The ease of operation coupled with ease of training result in staff competent in the use of RBSS systems. Furthermore, support structures in the Middle East help ensure operation of the systems with less downtime.

Related Links:
Roche 
Arab Health Congress